Insights
Search Results
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
10.17.25
Wilson Sonsini Advises Omeros on Asset Purchase and License Agreement with Novo Nordisk
On October 15, 2025, Novo Nordisk and Omeros Corporation announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (OMS906) in clinical development for rare blood and kidney disorders. Wilson Sonsini Goodrich & Rosati advised Omeros on the transaction.
Client Highlights
7.25.25
Wilson Sonsini Advises Revival on Strategic Partnership with Olympus
On July 25, 2025, Revival Healthcare Capital (Revival), an investment firm focused on transformative external innovation partnerships in MedTech, announced a strategic partnership with Olympus Corporation (Olympus), a global healthcare leader committed to making people’s lives healthier, safer, and more fulfilling through advanced medical technologies and solutions. The partnership is aimed at harnessing external innovation to accelerate development and market entry for an endoluminal robotics platform initially targeting gastrointestinal (GI) treatments. Wilson Sonsini Goodrich & Rosati advised Revival on the transaction and on fund matters related to the transaction.
Client Highlights
1.13.25
Wilson Sonsini Advises Light Horse Therapeutics on $62 Million Series A
Wilson Sonsini advised Light Horse Therapeutics, a developer of small molecule therapeutics, on its debut $62 million Series A financing. The financing, announced on January 9, 2025, was led by founding investor Versant Ventures and included Mubadala Capital as well as three strategic investors: Bristol-Myers Squibb Co, Taiho Ventures, and AbbVie. Light Horse is the latest company started by Versant’s Inception Discovery Engine, and its scientific co-founders are Brian Liau, Ph.D., Ben Cravatt, Ph.D., and Nathanael Gray, Ph.D.
Client Highlights
1.13.25
Wilson Sonsini Advises Light Horse Therapeutics on Strategic Collaboration with Novartis
Wilson Sonsini advised Light Horse Therapeutics, a developer of small molecule therapeutics, on its multi-target collaboration with Novartis to identify and develop therapeutics using the biotech’s proprietary platform. Under the terms of the agreement, announced on January 9, 2025, Light Horse will receive a $25 million upfront payment. The company is also eligible for $1 billion in further research, development, and sales milestones, in addition to royalties on licensed therapeutics. Further details are undisclosed.
Client Highlights
12.11.24
Wilson Sonsini Advises Cimeio Therapeutics on Partnership with Kyowa Kirin
On December 9, 2024, Cimeio Therapeutics, an immunotherapy company, announced that it has entered a research collaboration with Kyowa Kirin to develop novel cell therapies. Wilson Sonsini Goodrich & Rosati advised Cimeio on the transaction.
Client Highlights
10.22.24
Wilson Sonsini Advises Novo Holdings and F-Prime Capital on AvenCell’s $112 Million Series B
On October 22, 2024, AvenCell Therapeutics, a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, announced that it has raised $112 million in Series B financing. The financing was led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, and NYBC Ventures also participated in the round alongside founding investor Blackstone Life Sciences. Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction.
Client Highlights
8.23.24
Wilson Sonsini Advises Borealis Biosciences on $150 Million Series A and Strategic Collaboration Funding
On August 22, 2024, Borealis Biosciences (Borealis), a next-generation RNA medicines company, emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research collaboration funding from Novartis. Wilson Sonsini Goodrich & Rosati advised Borealis on the transaction.
Client Highlights
8.09.24
Wilson Sonsini Advises Recursion on Definitive Agreement with Exscientia
On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.
Client Highlights
7.11.24
Wilson Sonsini Advises Fluent BioSciences on Acquisition by Illumina
On July 9, 2024, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it has acquired Fluent BioSciences (Fluent), developer of an emerging and highly differentiated single-cell technology. Wilson Sonsini Goodrich & Rosati advised Fluent on the transaction.
Client Highlights
5.29.24
Wilson Sonsini Advises Radar Therapeutics on IP Matters Related to $13.4 Million Seed Funding
On May 23, 2024, Radar Therapeutics, a biotech company developing smart programmable medicines, announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC, and other investors. Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related to the transaction.
Client Highlights
5.07.24
Wilson Sonsini Advises SR One, Norwest Venture Partners, and Delos Capital in Zenas BioPharma's Upsized $200 Million Series C
On May 7, 2024, Zenas BioPharma, a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies, announced an upsized $200 million Series C preferred stock financing led by SR One, along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital. Also participating in the financing are new investors Federated Hermes Kaufmann Funds and Arrowmark Partners, along with existing investors, Fairmount, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and Superstring Capital. Wilson Sonsini Goodrich & Rosati advised SR One, Norwest Venture Partners, and Delos Capital on the transaction.